Skip to main content
SciBX: Science-Business eXchange
As published Thursday, September 25, 2014


  • Cover Story: Interrupting Ebola

    By Tracey Baas, Senior Editor

    Interrupting Ebola

    The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given an experimental combination of mAbs are still alive. But that therapy is only one of several in development, and it is all hands on deck now to push the programs into the clinic.

    Full Article
  • Canadian accelerant

    Two Canadian venture firms and a government-funded program have launched Canada's first national health science accelerator, Accel-Rx, to reignite local VC interest in funding early stage biotechs.

  • ALK7's obese functions

    Researchers have shown that inhibiting ALK7 can increase energy expenditure in fat cells and suggest the protein could be a target for obesity. Acceleron Pharma has licensed the findings and is pursuing a discovery program for ALK7 antagonists.

Distillery

  • This Week in Therapeutics

    Disrupting AURKA's active conformation to treat MYCN-driven cancers; inhibiting ERdj3 to treat Gaucher's disease; using noninvasive electromagnetic stimulation to improve associative memory; and more...

  • more therapeutics news
  • This Week in Techniques

    Activity-directed synthesis of bioactive scaffolds; CRISPR-Cas9 genome editing for latent viral infections; nanoparticles encoding the AEG1 promoter for prostate cancer imaging; and more...

  • more techniques news
Subscribe Now
Free Trial